abexxa

News

Boehringer Ingelheim has agreed to buy US biotech Abexxa Biologics, its second acquisition in the cancer immunotherapy area in the space of a year.

News

Belgian biotech UCB has made its second acquisition of the year, buying T-cell engager player Candid Therapeutics for up to $2.2 billion.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.